Cargando…
Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching
INTRODUCTION: Current treatment with vasodilators for pulmonary hypertension associated with respiratory diseases is limited by their inhibitory effect on hypoxic pulmonary vasoconstriction (HPV) and uncoupling effects on ventilation-perfusion (V’/Q’). Hypoxia is also a well-known modulator of the n...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783366/ https://www.ncbi.nlm.nih.gov/pubmed/29364918 http://dx.doi.org/10.1371/journal.pone.0191239 |
_version_ | 1783295261216342016 |
---|---|
author | Chamorro, Virginia Morales-Cano, Daniel Milara, Javier Barreira, Bianca Moreno, Laura Callejo, María Mondejar-Parreño, Gema Esquivel-Ruiz, Sergio Cortijo, Julio Cogolludo, Ángel Barberá, Joan A. Perez-Vizcaino, Francisco |
author_facet | Chamorro, Virginia Morales-Cano, Daniel Milara, Javier Barreira, Bianca Moreno, Laura Callejo, María Mondejar-Parreño, Gema Esquivel-Ruiz, Sergio Cortijo, Julio Cogolludo, Ángel Barberá, Joan A. Perez-Vizcaino, Francisco |
author_sort | Chamorro, Virginia |
collection | PubMed |
description | INTRODUCTION: Current treatment with vasodilators for pulmonary hypertension associated with respiratory diseases is limited by their inhibitory effect on hypoxic pulmonary vasoconstriction (HPV) and uncoupling effects on ventilation-perfusion (V’/Q’). Hypoxia is also a well-known modulator of the nitric oxide (NO) pathway, and may therefore differentially affect the responses to phosphodiesterase 5 (PDE5) inhibitors and soluble guanylyl cyclase (sGC) stimulators. So far, the effects of the sGC stimulator riociguat on HPV have been poorly characterized. MATERIALS AND METHODS: Contraction was recorded in pulmonary arteries (PA) in a wire myograph. Anesthetized rats were catheterized to record PA pressure. Ventilation and perfusion were analyzed by micro-CT-SPECT images in rats with pulmonary fibrosis induced by bleomycin. RESULTS: The PDE5 inhibitor sildenafil and the sGC stimulator riociguat similarly inhibited HPV in vitro and in vivo. Riociguat was more effective as vasodilator in isolated rat and human PA than sildenafil. Riociguat was ≈3-fold more potent under hypoxic conditions and it markedly inhibited HPV in vivo at a dose that barely affected the thromboxane A(2) (TXA(2)) mimetic U46619-induced pressor responses. Pulmonary fibrosis was associated with V’/Q’ uncoupling and riociguat did not affect the V’/Q’ ratio. CONCLUSION: PDE5 inhibitors and sGC stimulators show a different vasodilator profile. Riociguat was highly effective and potentiated by hypoxia in rat and human PA. In vivo, riociguat preferentially inhibited hypoxic than non-hypoxic vasoconstriction. However, it did not worsen V’/Q’ coupling in a rat model of pulmonary fibrosis. |
format | Online Article Text |
id | pubmed-5783366 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-57833662018-02-08 Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching Chamorro, Virginia Morales-Cano, Daniel Milara, Javier Barreira, Bianca Moreno, Laura Callejo, María Mondejar-Parreño, Gema Esquivel-Ruiz, Sergio Cortijo, Julio Cogolludo, Ángel Barberá, Joan A. Perez-Vizcaino, Francisco PLoS One Research Article INTRODUCTION: Current treatment with vasodilators for pulmonary hypertension associated with respiratory diseases is limited by their inhibitory effect on hypoxic pulmonary vasoconstriction (HPV) and uncoupling effects on ventilation-perfusion (V’/Q’). Hypoxia is also a well-known modulator of the nitric oxide (NO) pathway, and may therefore differentially affect the responses to phosphodiesterase 5 (PDE5) inhibitors and soluble guanylyl cyclase (sGC) stimulators. So far, the effects of the sGC stimulator riociguat on HPV have been poorly characterized. MATERIALS AND METHODS: Contraction was recorded in pulmonary arteries (PA) in a wire myograph. Anesthetized rats were catheterized to record PA pressure. Ventilation and perfusion were analyzed by micro-CT-SPECT images in rats with pulmonary fibrosis induced by bleomycin. RESULTS: The PDE5 inhibitor sildenafil and the sGC stimulator riociguat similarly inhibited HPV in vitro and in vivo. Riociguat was more effective as vasodilator in isolated rat and human PA than sildenafil. Riociguat was ≈3-fold more potent under hypoxic conditions and it markedly inhibited HPV in vivo at a dose that barely affected the thromboxane A(2) (TXA(2)) mimetic U46619-induced pressor responses. Pulmonary fibrosis was associated with V’/Q’ uncoupling and riociguat did not affect the V’/Q’ ratio. CONCLUSION: PDE5 inhibitors and sGC stimulators show a different vasodilator profile. Riociguat was highly effective and potentiated by hypoxia in rat and human PA. In vivo, riociguat preferentially inhibited hypoxic than non-hypoxic vasoconstriction. However, it did not worsen V’/Q’ coupling in a rat model of pulmonary fibrosis. Public Library of Science 2018-01-24 /pmc/articles/PMC5783366/ /pubmed/29364918 http://dx.doi.org/10.1371/journal.pone.0191239 Text en © 2018 Chamorro et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Chamorro, Virginia Morales-Cano, Daniel Milara, Javier Barreira, Bianca Moreno, Laura Callejo, María Mondejar-Parreño, Gema Esquivel-Ruiz, Sergio Cortijo, Julio Cogolludo, Ángel Barberá, Joan A. Perez-Vizcaino, Francisco Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching |
title | Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching |
title_full | Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching |
title_fullStr | Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching |
title_full_unstemmed | Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching |
title_short | Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching |
title_sort | riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783366/ https://www.ncbi.nlm.nih.gov/pubmed/29364918 http://dx.doi.org/10.1371/journal.pone.0191239 |
work_keys_str_mv | AT chamorrovirginia riociguatversussildenafilonhypoxicpulmonaryvasoconstrictionandventilationperfusionmatching AT moralescanodaniel riociguatversussildenafilonhypoxicpulmonaryvasoconstrictionandventilationperfusionmatching AT milarajavier riociguatversussildenafilonhypoxicpulmonaryvasoconstrictionandventilationperfusionmatching AT barreirabianca riociguatversussildenafilonhypoxicpulmonaryvasoconstrictionandventilationperfusionmatching AT morenolaura riociguatversussildenafilonhypoxicpulmonaryvasoconstrictionandventilationperfusionmatching AT callejomaria riociguatversussildenafilonhypoxicpulmonaryvasoconstrictionandventilationperfusionmatching AT mondejarparrenogema riociguatversussildenafilonhypoxicpulmonaryvasoconstrictionandventilationperfusionmatching AT esquivelruizsergio riociguatversussildenafilonhypoxicpulmonaryvasoconstrictionandventilationperfusionmatching AT cortijojulio riociguatversussildenafilonhypoxicpulmonaryvasoconstrictionandventilationperfusionmatching AT cogolludoangel riociguatversussildenafilonhypoxicpulmonaryvasoconstrictionandventilationperfusionmatching AT barberajoana riociguatversussildenafilonhypoxicpulmonaryvasoconstrictionandventilationperfusionmatching AT perezvizcainofrancisco riociguatversussildenafilonhypoxicpulmonaryvasoconstrictionandventilationperfusionmatching |